Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
about
Milnacipran versus other antidepressive agents for depressionInhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migrationDepression rating scales in Parkinson's disease: critique and recommendations.Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblastsChanges in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trialsBosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.Is duloxetine's effect on painful physical symptoms in depression an indirect result of improvement of depressive symptoms? Pooled analyses of three randomized controlled trialsCirculating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure.Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentaryShort and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses.A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis.Simvastatin attenuates pulmonary vascular remodelling by down-regulating matrix metalloproteinase-1 and -9 expression in a carotid artery-jugular vein shunt pulmonary hypertension model in rats.Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPsBosentan for the treatment of scleroderma
P2860
Q24240125-E5E0F2DD-C9C2-4B20-88F4-8EAA19F02DB6Q24812224-30DC3074-BAA4-4C24-B409-158644F303FCQ34578187-40D5DCC9-4C2F-40AC-9556-C04A04DAD516Q36023711-465EC5F8-D0F4-4682-B44B-41545D336FCBQ36380157-8746F131-D3C5-489B-9635-652E82A79C38Q36543145-1DAE2CD6-939B-4F26-A4CE-8549A2E4622CQ36574971-2EC5A575-4661-472C-977B-D689280DFB12Q37071471-91823501-EA77-44A4-8DFC-8017323A67A8Q37449200-3BCF3EDA-6A7B-4992-8284-B3ECA7A3AB9FQ42854385-5840E3EA-3E36-40D1-8432-93515E6DEF46Q53575290-21A03213-C757-4A2F-BC2A-3A0011475503Q54286592-A5E78F22-2706-4A81-80AE-970FC1FD76F7Q56974646-C20E454A-2BC8-41F8-8661-0DE2F387AD51Q56978245-04AD727E-AE07-4216-8D60-4614267A5C14
P2860
Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
@ast
Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
@en
type
label
Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
@ast
Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
@en
prefLabel
Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
@ast
Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
@en
P356
P1476
Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
@en
P2093
Alan D Ogilvie
Joubert Gama
P304
P356
10.1185/030079905X30680
P407
P577
2005-03-01T00:00:00Z